Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Authors' conclusion
Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants with type 2 diabetes.
Study context
- Population
- Participants with T2DM and chronic kidney disease (CKD); CKD severity by eGFR <60 or ≥60 mL/min/1.73 m², UACR <300 or ≥300 mg/g, or Kidney Disease Improving Global Outcomes (KDIGO) risk classification
- Participants
- 3,533 participants
- Comparison
- Semaglutide 1 mg SC weekly vs placebo, by baseline CKD severity
- Primary endpoint
- Cardiovascular (CV) death/myocardial infarction (MI)/stroke (CV death, non-fatal MI or non-fatal stroke) and all-cause death, by baseline CKD severity
- Follow-up
- Median 3.4 years
Methodological detailsprespecified analyses, placebo-controlled, KDIGO risk at baseline: low/moderate 242 (6.8%), high 878 (24.9%), very high 2412 (68.3%)
- Prespecified analyses
- Placebo-controlled
- KDIGO risk at baseline: low/moderate 242 (6.8%), high 878 (24.9%), very high 2412 (68.3%)
Primary result
As reported in the abstract
Semaglutide vs PlaceboHazard ratio (95% CI)P value
CV death/MI/stroke; consistent across eGFR, UACR and KDIGO categories (all P-interaction > .13)
0.82(0.68–0.98)
P = 0.03All-cause death; consistent across eGFR and KDIGO (P-interaction .21 and .23)
0.80(0.67–0.95)
P = 0.01- All-cause death, UACR <300 mg/g: HR
- 1.17 (0.83-1.65)
- All-cause death, UACR ≥300 mg/g: HR
- 0.70 (0.57-0.85)
Original publication
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J. Published 30 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →